AnalyzeDirect

Cardamone M, Flanagan D, Mowat D, Kennedy SE, Chopra M, Lawson JA. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex. J Pediatr. May 2014;164(5):1195-1200.

Publication Date
May 2014

How Analyze was Used
“The volumes of the SEGAs [subependymal giant cell astrocytomas] were calculated with the use of ANALYZE 10 software program (AnalyzeDirect Inc, Overland Park, Kansas) using a 1.5-T MRI device. We used a 1-sided paired t-test to evaluate the mean reduction in the volume of an SEGA from baseline volume using an α level of .05.”

Keywords
Adolescent
Anticonvulsants/therapeutic use
Antineoplastic Agents/therapeutic use
Astrocytoma/drug therapy/etiology
Child
Child, Preschool
Epilepsy/drug therapy/etiology
Female
Humans
Male
Prospective Studies
Sirolimus/analogs & derivatives/therapeutic use
TOR Serine-Threonine Kinases/antagonists & inhibitors
Treatment Outcome
Tuberous Sclerosis/complications

Author Affiliation(s)
Department of Neurology, Sydney Children’s Hospital, Randwick, New South Wales, Australia. (MC, DF, JAL)

Department of Medical Genetics, Sydney Children’s Hospital, Randwick, New South Wales, Australia. (DM, MC)

Department of Nephrology, Sydney Children’s Hospital, Randwick, New South Wales, Australia. (SEK)

The School of Women’s and Children’s Health, Medicine UNSW, University of New South Wales, Sydney, New South Wales, Australia. (MC, DF, DM, SEK, JAL)

ID# 31

Tags: Adolescent, Anticonvulsants/therapeutic use, Antineoplastic Agents/therapeutic use, Astrocytoma/drug therapy/etiology, Child, Epilepsy/drug therapy/etiology, Female, Humans, Male, Preschool Child, Prospective Studies, Sirolimus/analogs & derivatives/therapeutic use, TOR Serine-Threonine Kinases/antagonists & inhibitors, Treatment Outcome, Tuberous Sclerosis/complications